# Immune Dysfunction in HIV associated Lung Cancer (Immuno/Microenvironment)

> **NIH NIH P30** · YALE UNIVERSITY · 2024 · $249,987

## Abstract

OVERALL
PROJECT SUMMARY
Yale Cancer Center (YCC) seeks to be a leader in eliminating the burden of cancer through transformative
research, with attention to the needs of all people facing this disease. We will work collaboratively to pursue this
goal with a relentless focus on reducing cancer disparities, while maximizing access to care, addressing the
needs of the community, ensuring equity and diversity in our workplace, and training future cancer researchers,
clinicians, and leaders. For fifty years, YCC has conducted high-impact cancer research, and today a deep
culture of collaboration unites 305 basic, translational, population, and clinical scientists focused on cancer. YCC
members conduct research to understand and prevent cancer, detect cancer early, and treat cancer more
effectively. Based on the recognition that many individuals do not receive the best care, YCC will mount a major
effort to understand the basis for disparities in cancer care and outcomes and to use this knowledge to combat
these disparities through enhanced research in our Catchment Area in partnership with our local community.
This effort will be reinforced by a plan to increase the diversity of the YCC staff through directed recruitments
and promotions and through reinvigorated training and education efforts. Six Research Programs are the heart
of YCC research, resulting in 2422 publications during the current project period, 30% in high-impact journals.
The Research Programs are led by basic, translational, clinical, and population scientists working in partnership
to foster transdisciplinary research. YCC supports and manages Shared Resources that provide exceptional
state-of-the-art technologies to enable groundbreaking discoveries. YCC investigators conduct a growing
number of innovative clinical trials that translate laboratory discoveries into the clinic and incorporate novel
designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new
therapeutic approaches. This work relies on close partnerships between laboratory and clinical researchers.
Clinical trials led by YCC investigators during the current project period led to breakthroughs in cancer treatment
including five FDA approvals. Since 2018, overall cancer funding (direct costs) increased 6.6% to $94.9M,
including a 9% increase in NCI funding to $26.5M. YCC holds three NCI SPORE grants, numerous U-type and
other multi-investigator grants, and a leadership role in a SU2C Dream Team award. $1.9M in CCSG internal
grant funding distributed 2016-2021 resulted in $23.2M in external funds that could be directly linked back to
these internal grants, a 12.3-fold return on investment. Importantly, during the current project period, the YCC
leveraged these CCSG funds with philanthropic and other sources to generate a total of $10.2M distributed as
peer reviewed internal grants for cancer research. Over the next five years, YCC will continue to develop
initiatives and re...

## Key facts

- **NIH application ID:** 11069075
- **Project number:** 3P30CA016359-44S4
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Eric P. Winer
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $249,987
- **Award type:** 3
- **Project period:** 1997-07-01 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11069075

## Citation

> US National Institutes of Health, RePORTER application 11069075, Immune Dysfunction in HIV associated Lung Cancer (Immuno/Microenvironment) (3P30CA016359-44S4). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11069075. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*